|
Post by peppy on Jul 10, 2015 4:04:39 GMT -5
Marketing. The following is the marketing video targeted for the physician. www.afrezzapro.com/ www.afrezzapro.com/how-afrezza-works
The information presented in the video is study information. A commercial will probably only be allowed to present study information along with a visual of a happy afrezza user smiling at a meal.
The physician information doesn't mention that afrezza delivers insulin into the blood as a monomer where exubera delivered insulin into the lungs/blood as a hexamer.
It is however a fact as we have been given to understand that afrezza delivers insulin as a monomer. If that fact can be made known, it opens up the discussion. It helps explain the difference in pharm kinetics that can be shown. Attachment Deleted Afrezza.... it is a monomer. Afrezza...insulin delivered as a monomer. Afrezza.....technosphere insulin, insulin delivered as a monomer.
A fact. A distinguishing fact. A fact that treats people like adults, opens up our minds, and makes us google. A fact not mentioned in the physician information. hmmm. Just sayin. It is the fact that made Al Mann go after this. Just sayin.
|
|
|
Post by peppy on Jul 10, 2015 5:23:14 GMT -5
What can a commercial say?
Afrezza® inhaled insulin effectively lowered A1C in adults with type 2 diabetes uncontrolled on OADs Study design
Afrezza® efficacy was studied in a 24-week, double-blind, placebo-controlled trial (N=479) of adults with type 2 diabetes uncontrolled (A1C >7%) on optimal/maximally tolerated doses of either metformin alone or 2 or more OADs. Patients were treated with Afrezza® + OADs or inhaled placebo powder without insulin + OADs.
Twice as many patients treated with Afrezza® + OADs achieved an A1C of ≤7% vs placebo + OADs1 At baseline, Afrezza® + OADs group had a mean A1C of 8.25% vs 8.27% in the placebo + OADs group At week 24, 32.2% of patients treated with Afrezza® + OADs achieved an A1C ≤7% vs 15.3% of patients on placebo + OADs
In adults with type 1 diabetes, the efficacy of Afrezza® inhaled insulin proved noninferior to that of insulin aspart within the preset noninferiority margin of 0.4%
Study design and results
In a 24-week, open-label, active-controlled study, the efficacy of Afrezza®+ injectable basal insulin was evaluated in patients whose diabetes was uncontrolled.1 At Week 24, patients treated with Afrezza® + basal insulin (n=174) had a 0.21% A1C reduction vs 0.40% in those treated with basal insulin (n=170) Difference between the 2 groups was 0.19% (95% CI: 0.02, 0.36)
Afrezza® provided less A1C reduction than insulin aspart, and the difference was statistically significant More subjects in the insulin aspart group achieved A1C target of ≤7%.
|
|
|
Post by me on Jul 10, 2015 8:00:11 GMT -5
Sales are always the determining factor. Scripts need to keep climbing and sales need to increase. We don't want Sanofi to have any other choice then to continue on with Afrezza in 2016. If sales meander as they are, I'd be very worried come early next year. That's why we want to see the urgency of getting the word out. Get it on TV NOW! "If sales meander as they are" You must be privy to some information the rest of us poor ignorami do not have. You nor anyone else have any idea whatsoever what sales are. You nor anyone else have any idea what actual script counts are. Even the extrapolated Symphony results are running at least 8 weeks behind the actual demand curve - it cannot be otherwise with the well-established 8 week (or more) delay between the time a patient begins pursuing a prescription and the time they actually obtain the prescription and take it to the pharmacy where it gets captured in Symphony. Do you know how many prescriptions are underway right now waiting to be completed? No. Barely 5 months into a launch - everyone in the world knows there is an effective 6 month moratorium on DTC for new drug launches. That is well established - I was personally surprised to see even the magazine ads this early. This is essentially a 5-month old infant and you folks are expecting it to be reading, writing, and running like a ten year old. As any investor who has made REAL money in the market knows, it takes time and patience. I personally have zero sympathy for anyone who cannot go even a few months without crying about how incompetent and useless management is. The very same management who have brought one of the most phenomenal drugs ever devised to market against great odds, and without whom the investment would not even be possible. Sanofi is a world class organization and just because they are not catering to the impatient "needs" of short term oriented "investors" does not mean they are not doing what they view as appropriate at this stage of the launch. I'm not even going to reply to any other replies - it is just a waste of effort because there is no patience on the part of all too many posters and I have no patience for people who do not have patience. I guarantee you Al Mann is not concerned about whether or not he sees a TV ad next week. Dudley, thank you for this.
|
|
|
Post by mnholdem on Jul 10, 2015 9:56:17 GMT -5
I suspect that many of the so-called "short term" investors are those who jumped on board last spring/summer when MNKD shot up from $3 to $11 per share in a very short period of time. Perhaps now they are in the red and are impatiently expecting the share price to explode again?
For the impatient, it seems to be somewhat beneficial for some of these shorter-term investors to read a calming post every now and then. Thanks for the post, Dudley.
|
|
|
Post by stevil on Jul 10, 2015 11:54:01 GMT -5
Good news (albeit small).
Just got done talking to my pharmacist friend. He said Afrezza was featured in this quarter's Pharmacy MPR. It's a quarterly informational journal used to educate pharmacists.
So word is slowly getting out. Making progress...
|
|
|
Post by nccapitalist on Jul 10, 2015 12:08:44 GMT -5
I suspect that many of the so-called "short term" investors are those who jumped on board last spring/summer when MNKD shot up from $3 to $11 per share in a very short period of time. Perhaps now they are in the red and are impatiently expecting the share price to explode again? For the impatient, it seems to be somewhat beneficial for some of these shorter-term investors to read a calming post every now and then. Thanks for the post, Dudley. Gave myself an early Christmas present with an initial purchase of MNKD shares on 12/13/10. Unfortunately the price was $8. I'm in it for the long haul anyway but just concerned about keeping this company alive, that's my drive.
|
|